Preparation method of polycation / cascade protein preparation with antibacterial and anti-inflammatory functions, product and application

By preparing polycation/cascade protein preparations, combined with electrostatic action to form nanoparticles, the problem of treatment of inflammatory diseases caused by bacterial infection is solved, effective bactericidal and anti-inflammatory effects are achieved, the inflammation level is reduced, and immune function is restored. It is suitable for Various bacterial infections.

CN118903391APending Publication Date: 2024-11-08BEIJING UNIV OF CHEM TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410907662.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-08
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The treatment of inflammatory diseases caused by bacterial infection is difficult to effectively solve, especially due to oxidative stress and immune system collapse caused by bacterial stimulation, which leads to limited antibacterial treatment effects, and existing antibacterial materials have limited effectiveness in controlling inflammation.

Method used

By preparing polycation/cascade protein preparations with antibacterial and anti-inflammatory functions, the positively charged polycations are combined with cascade proteins (fusion proteins of superoxide dismutase and catalase) to form nanometers by electrostatic action. Granules, both have bactericidal effects and can deliver antioxidant enzymes to regulate ROS levels in cells and reduce inflammation.

Benefits of technology

This preparation significantly improves bactericidal and anti-inflammatory properties in diseases such as periodontitis and osteomyelitis, reduces inflammation levels, restores immune function, and has simple process, low cost and good safety. It is suitable for multiple bacterial infections caused by various bacterial infections. disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903391A_ABST
    Figure CN118903391A_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method of a polycation / cascade protein preparation with antibacterial and anti-inflammatory functions, a compound is formed by positively charged polycation and cascade protein through electrostatic interaction, and the preparation method comprises the following steps: 1) preparing cascade protein; the cascade protein is a cascade protein expressed by fusion plasmids of superoxide dismutase and catalase; and 2) respectively preparing the polycation and the cascade protein into solutions, and blending according to the mass ratio of (5: 1)-(15: 1) to obtain the polycation / cascade protein. According to the invention, the polycation and the cascade protein SOAT are complexed into the polycation / cascade protein compound through electrostatic adsorption, so that the pathological characteristics of bacterial inflammatory diseases (periodontitis, osteomyelitis and the like) can be combined, and the bactericidal and anti-inflammatory properties can be improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of pharmaceutical application technology and relates to a preparation method, product and application of a polycationic / cascade protein preparation with antibacterial and anti-inflammatory functions. Background Art

[0002] Bacterial infectious diseases are increasingly endangering human life and health. According to statistics from the World Health Organization, by 2050, the number of deaths from bacterial infections each year may exceed 10 million, which will far exceed the number of deaths from cancer. In addition, planktonic bacteria aggregate and adhere to the surface to form a dense, difficult-to-eradicate biofilm, which increases the difficulty of treatment. At the same time, continuous bacterial stimulation causes cells to continuously produce reactive oxygen species (ROS), further activating immune cells and secreting high levels of cytokines. Although these immune cells and cytokines have a bactericidal effect, they also put cells in a state of oxidative stress. The elevated level of inflammation increases the patient's pain and may also bring serious systemic sequelae: under the stimulation of inflammation, cells produce more ROS, which may eventually cause an inflammatory factor storm, multiple organ failure, and immune system collapse. The body's immune deficiency further limits the effectiveness of antibacterial treatment, resulting in a vicious cycle of "bacterial stimulation-oxidative stress-immune collapse". Therefore, it is necessary to develop efficient antibacterial and inflammatory regulatory materials to solve the problem of treating bacterial inflammatory diseases.

[0003] In order to overcome diseases caused by bacterial infections, various antibacterial materials have been widely developed. Among them, cationic polymers can combine with negatively charged bacterial membranes due to their positive charge, showing certain antibacterial effects. Polymers with quaternary ammonium groups can destroy the integrity of bacterial membranes, causing the bacterial contents to leak and causing bacterial death. At the same time, cationic polymers can combine with negatively charged or hydrophobic small molecule drugs and biomacromolecule drugs (nucleic acids, proteins, etc.), helping them to cross multiple biological barriers, protect them from degradation or removal, and deliver them into cells to play a role, which has development prospects in the treatment of bacterial inflammatory diseases. Eliminating excessive ROS may be an important means to control the development of inflammation, and natural oxidoreductases have broad application prospects in biotechnology, biomedicine and pharmaceutical fields. The antioxidant system of an organism is defined as an oxidative defense system. It is worth noting that the antioxidant defense system should not completely eliminate ROS, but maintain normal ROS levels so that they can play their proper functions. The complex antioxidant defense system includes endogenous antioxidant enzymes, mainly SOD, CAT and glutathione peroxidase (GPx), as well as small molecule scavengers, including vitamins, β-carotene, coenzyme Q, selenium and zinc. Direct delivery of antioxidant enzymes into cells is also one of the strategies to effectively alleviate cellular oxidative damage. In addition to single enzyme delivery systems, researchers are no longer satisfied with delivering only one antioxidant enzyme into cells at the same time. In order to obtain higher ROS removal efficiency, multi-enzyme co-delivery systems have gradually been proposed. Summary of the invention

[0004] In view of this, the present invention provides a preparation method, product and application of a polycationic / cascade protein preparation with antibacterial and anti-inflammatory functions. The present invention specifically provides the following technical solutions:

[0005] 1. A method for preparing a polycationic / cascade protein preparation with antibacterial and anti-inflammatory functions, wherein a positively charged polycation and a cascade protein form a complex through electrostatic interaction, and the preparation steps are as follows:

[0006] 1) preparing a cascade protein, wherein the cascade protein is a cascade protein expressed by a superoxide dismutase and catalase fusion plasmid;

[0007] 2) The polycation and the cascade protein are separately prepared into solutions, and mixed at a mass ratio of 5:1 to 15:1 to obtain polycation / cascade protein.

[0008] Furthermore, the molecular weight of the cascade protein in step 1) is 80 kDa.

[0009] Furthermore, the polycation and cascade protein described in step 2) are blended in a mass ratio of 5:1.

[0010] Furthermore, the concentration of the cascade protein solution in step 2) is 1-5 mg / mL, and the concentration of the polycation solution is 1-5 mg / mL.

[0011] Further, the polycation in step 2) is β-CD-g-PSS20 or polyhexamethylene biguanide, and the structural formula of the β-CD-g-PSS20 is: The number average molecular weight of the polyhexamethylene biguanide is 2190-2928.

[0012] Furthermore, the preparation method of the β-CD-g-PSS20 is as follows: using all-thiol-β-cyclodextrin as an initiator, initiating monomer lipoic acid-arginine to carry out disulfide exchange polymerization at 25° C. to 35° C., and terminating the polymerization with 2-iodoacetamide.

[0013] Furthermore, the preparation method of the cascade protein described in step 1) is to construct the sequences of superoxide dismutase and catalase into a prokaryotic expression vector, then express the cascade protein with competent cells, and obtain the cascade protein by nickel column purification.

[0014] 2. The polycationic / cascade protein preparation with antibacterial and anti-inflammatory functions prepared by the above preparation method has a particle size of 100-500nm.

[0015] 3. Application of the above-mentioned polycationic / cascade protein preparation with antibacterial and anti-inflammatory functions in combating periodontitis and osteomyelitis.

[0016] Furthermore, when the polycation is β-CD-g-PSS20, it is used for anti-peri-inflammatory effects, and when the polycation in the preparation is polyhexamethylene biguanide, it is used for anti-osteomyelitis.

[0017] The beneficial effects of the present invention are as follows: the present invention constructs the cascade protein SOAT through plasmid design and protein purification and other technologies, and SOAT has both catalase and superoxide dismutase activities, and can achieve inflammation regulation by removing a variety of reactive oxygen species (ROS). The present invention utilizes polycations and cascade protein SOAT to form a polycation / cascade protein complex through electrostatic adsorption, which can be combined with the pathological characteristics of bacterial inflammatory diseases (periodontitis and osteomyelitis, etc.) to enhance the bactericidal and anti-inflammatory properties. The polycation / cascade protein complex of the present invention is a positively charged nanoparticle, which, on the one hand, exerts an antibacterial effect; on the other hand, the cascade protein is delivered into the cell, and while antibacterial, intracellular ROS regulation is achieved, normal cell apoptosis is reduced, inflammation levels are reduced, the body's immunity is restored, and the efficacy of antibacterial drugs is restored, solving the problem of treating bacterial inflammatory diseases. The present invention is suitable for a variety of diseases caused by different bacterial infections, and the polycation system is β-CD-g-PSS 20The invention is suitable for anti-periodontitis, and the polyhexamethylene biguanide (PHMB) system is suitable for anti-osteomyelitis. The invention has simple preparation process, good controllability, simple process conditions, low production cost, easy raw materials, stable product performance, no need for chemical cross-linking agents, and good safety. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] In order to make the purpose, technical solution and beneficial effects of the present invention clearer, the present invention provides the following drawings:

[0019] Figure 1 Schematic diagram of the composition of the polycation / cascade protein preparation;

[0020] Figure 2 β-CD-g-PSS for Polycation / Cascade Protein Preparation 20 (SOAT) particle size potential map;

[0021] Figure 3 β-CD-g-PSS for Polycation / Cascade Protein Preparation 20 -1(SOAT) antibacterial performance diagram;

[0022] Figure 4 β-CD-g-PSS for Polycation / Cascade Protein Preparation 20 -1(SOAT) anti-inflammatory properties diagram;

[0023] Figure 5 Polycation / Cascade protein β-CD-g-PSS 20 -1(SOAT) cytotoxicity profile;

[0024] Figure 6 is the particle size potential diagram of the polycation / cascade protein preparation PMHB (SOAT);

[0025] Figure 7 is the antibacterial performance diagram of the polycationic / cascade protein preparation PMHB-1 (SOAT);

[0026] Figure 8 is the cytotoxicity graph of the polycation / cascade protein preparation PMHB-1 (SOAT); DETAILED DESCRIPTION

[0027] The preferred embodiments of the present invention are described in detail below in conjunction with the accompanying drawings.

[0028] The preparation principle of the polycation / cascade protein preparation of the present invention is as follows Figure 1 As shown, from Figure 1It can be seen that a protein preparation is obtained by using polycations to form a polycationic cascade protein complex by electrostatic interaction with cascade proteins. The polycationic protein complex has positive charge, and the polycation has bactericidal activity, while allowing cascade proteins to enter cells, effectively maintaining the anti-inflammatory activity of cascade proteins.

[0029] Example 1

[0030] 1) Preparation of polycation (β-CD-g-PSS 20 )

[0031] Using all-thiol-β-cyclodextrin (β-CD-SH) as an initiator, monomer lipoic acid-arginine (La-Arg) was initiated to undergo disulfide exchange polymerization in an acetate buffer at pH = 5 at 30°C, and the polymerization was terminated with 2-iodoacetamide. The solid was obtained by dialysis with deionized water and freeze-drying, referred to as β-CD-g-PSS. 20 .

[0032] 2) Design of cascade protein SOAT

[0033] The cascade protein of the present invention is a cascade protein of superoxide dismutase (SOD) and catalase (CAT), referred to as SOAT, with a molecular weight of 80 kDa. The cascade protein is obtained by laboratory expression and purification. The sequence of SOAT is:

[0034]

[0035]

[0036] 6×His was added to the back end of the SOAT sequence, and PET-28a was used as a vector to construct a SOAT protein expression plasmid.

[0037] 3) Preparation of Cascade Protein SOAT

[0038] The SOAT expression plasmid was transformed into BL21 (DE3) competent cells, and then the bacterial culture was added to LB bacterial culture medium containing 0.1% kanamycin, and the culture temperature was 37°C and the rotation speed was 220rpm. The cells were cultured in a shaker until OD600 was about 0.6, and isopropyl-β-D-thiogalactoside (IPTG) was added, and the final concentration of IPTG was 0.5mM. Low-temperature induction was performed at 16°C, and the cells were cultured in a shaker for 24h. The bacterial solution was divided into centrifuge tubes, centrifuged at 6000rpm for 6min at 4°C, the supernatant was discarded, and the precipitate was resuspended in sterile PBS. After the bacteria were ultrasonically broken in an ice bath, the ultrasonic power was 120W, the total ultrasonic time was 10min, the ultrasonic was turned on for 3s, and the ultrasonic was turned off for 7s. Centrifuged at 8000rpm for 6min at 4°C to remove bacterial fragments, and the supernatant was collected. The supernatant was purified in a nickel column, the protein was separated using Tris-HCl buffer containing different concentrations of imidazole, and the eluted protein solution was concentrated by ultrafiltration. The concentration of SOAT was tested using a BCA kit, and SOAT was stored in a -80°C refrigerator to avoid repeated freezing and thawing.

[0039] 4) Preparation of polycation / cascade protein preparations

[0040] The polycation was dissolved in deionized water and shaken to obtain a polycation solution of 1.25 mg / mL; the cascade protein was dissolved in deionized water to obtain a cascade protein solution of 1 mg / mL. The polycation solution and the cascade protein solution were added to a centrifuge tube at a mass ratio of 5:1, shaken and mixed, and then allowed to stand at a temperature of 25°C for 30 minutes to obtain a polycation / cascade protein complex nano solution. The obtained nano solution is a clear and transparent nano solution, referred to as β-CD-g-PSS. 20 -1(SOAT).

[0041] Example 2

[0042] Step 1) to step 3) are the same as in Example 1;

[0043] 4) Preparation of polycationic cascade protein β-CD-g-PSS 20 -2(SOAT)

[0044] Polycation β-CD-g-PSS 20Dissolve in deionized water, shake to obtain a polycationic solution, the solution is 1.25 mg / mL; dissolve cascade protein SOAT in deionized water to obtain a cascade protein solution, the solution is 1 mg / mL, add the polycationic solution and cascade protein solution into a centrifuge tube at a mass ratio of 8:1, shake and mix, and let stand at a temperature of 25°C for 30 minutes to obtain a polycationic cascade protein complex nano solution, referred to as β-CD-g-PSS 20 -2(SOAT).

[0045] Example 3

[0046] Step 1) to step 3) are the same as in Example 1;

[0047] 4) Preparation of polycationic / cascade protein preparation β-CD-g-PSS 20 -3(SOAT)

[0048] The polycation was dissolved in deionized water and shaken to obtain a polycation solution of 1.25 mg / mL; the cascade protein was dissolved in deionized water to obtain a cascade protein solution of 1 mg / mL. The polycation solution and the cascade protein solution were added to a centrifuge tube at a mass ratio of 10:1, shaken and mixed, and then allowed to stand at a temperature of 25°C for 30 minutes to obtain a polycation cascade protein complex nano solution. The obtained nano solution is a clear and transparent nano solution, referred to as β-CD-g-PSS. 20 -3(SOAT).

[0049] Example 4

[0050] Step 1) to step 3) are the same as in Example 1;

[0051] 4) Preparation of polycation / cascade protein β-CD-g-PSS 20 -4(SOAT)

[0052] The polycation was dissolved in deionized water and shaken to obtain a polycation solution of 1.25 mg / mL; the cascade protein was dissolved in deionized water to obtain a cascade protein solution of 1 mg / mL. The polycation solution and the cascade protein solution were added to a centrifuge tube at a mass ratio of 12:1, shaken and mixed, and then allowed to stand at a temperature of 25°C for 30 minutes to obtain a polycation cascade protein complex nano solution. The obtained nano solution is a clear and transparent nano solution, referred to as β-CD-g-PSS. 20 -4(SOAT).

[0053] Example 5

[0054] Step 1) to step 3) are the same as in Example 1;

[0055] 4) Preparation of polycation / cascade protein β-CD-g-PSS 20 -5(SOAT)

[0056] The polycation was dissolved in deionized water and shaken to obtain a polycation solution of 1.25 mg / mL; the cascade protein was dissolved in deionized water to obtain a cascade protein solution of 1 mg / mL. The polycation solution and the cascade protein solution were added to a centrifuge tube at a mass ratio of 15:1, shaken and mixed, and then allowed to stand at a temperature of 25°C for 30 minutes to obtain a polycation cascade protein complex nano solution. The obtained nano solution is a clear and transparent nano solution, referred to as β-CD-g-PSS. 20 -5(SOAT).

[0057] Example 6

[0058] 1) Preparation of polycation (polyhexamethylene biguanide)

[0059] Polyhexamethylene biguanide hydrochloride is dissolved in ultrapure water, dialyzed with a 1000 MWCO dialysis bag, and then freeze-dried to obtain polyhexamethylene biguanide, referred to as PHMB.

[0060] 2) Same as step 2 of Example 1)

[0061] 3) Same as step 3) in Example 1;

[0062] 4) Preparation of polycationic / cascade protein PHMB-1 (SOAT)

[0063] The polycation was dissolved in deionized water and shaken to obtain a polycation solution of 1.25 mg / mL; the cascade protein was dissolved in deionized water to obtain a cascade protein solution of 1 mg / mL, and the polycation solution and the cascade protein solution were added to a centrifuge tube at a mass ratio of 5:1, shaken and mixed, and then allowed to stand at a temperature of 25°C for 30 minutes to obtain a polycation cascade protein complex nano solution. The obtained nano solution is a clear and transparent nano solution, referred to as PHMB-1 (SOAT).

[0064] Example 7

[0065] Step 1) to step 3) are the same as in Example 6;

[0066] 4) Preparation of polycationic / cascade protein PHMB-2 (SOAT)

[0067] The polycation was dissolved in deionized water and shaken to obtain a polycation solution of 1.25 mg / mL; the cascade protein was dissolved in deionized water to obtain a cascade protein solution of 1 mg / mL, and the polycation solution and the cascade protein solution were added to a centrifuge tube at a mass ratio of 7.5:1, shaken and mixed, and then allowed to stand at a temperature of 25°C for 30 minutes to obtain a polycation cascade protein complex nano solution. The obtained nano solution is a clear and transparent nano solution, referred to as PHMB-2 (SOAT).

[0068] Example 8

[0069] Step 1) to step 3) are the same as in Example 6;

[0070] 4) Preparation of polycationic / cascade protein PHMB-3 (SOAT)

[0071] The polycation was dissolved in deionized water and shaken to obtain a polycation solution of 1.25 mg / mL; the cascade protein was dissolved in deionized water to obtain a cascade protein solution of 1 mg / mL, and the polycation solution and the cascade protein solution were added to a centrifuge tube at a mass ratio of 10:1, shaken and mixed, and then allowed to stand at a temperature of 25°C for 30 minutes to obtain a polycation cascade protein complex nano solution. The obtained nano solution is a clear and transparent nano solution, referred to as PHMB-3 (SOAT).

[0072] Example 9

[0073] Step 1) to step 3) are the same as in Example 6;

[0074] 4) Preparation of polycationic / cascade protein PHMB-4 (SOAT)

[0075] The polycation was dissolved in deionized water and shaken to obtain a polycation solution of 1.25 mg / mL; the cascade protein was dissolved in deionized water to obtain a cascade protein solution of 1 mg / mL, and the polycation solution and the cascade protein solution were added to a centrifuge tube at a mass ratio of 15:1, shaken and mixed, and then allowed to stand at a temperature of 25°C for 30 minutes to obtain a polycation cascade protein complex nano solution. The obtained nano solution is a clear and transparent nano solution, referred to as PHMB-4 (SOAT).

[0076] Test Example 1 Particle Size Potential Table Test

[0077] After diluting the polycationic cascade protein complex prepared in Examples 1-5, 1 mL was taken out and the hydrated particle size and surface potential were measured on a Malvern dynamic light scattering instrument. After diluting the polycationic / cascade protein complex prepared in Example, 1 mL was taken out and the hydrated particle size and potential were measured on a Malvern dynamic light scattering instrument. Figure 2 Particle size potential plots for polycation / cascade protein preparations.

[0078] from Figure 2 It can be seen that:

[0079] As a negatively charged protein, SOAT alone is difficult to achieve effective cellular endocytosis and requires the help of cationic polymer carriers. 20 Mixed with SOAT, positively charged nanoparticles are obtained, which are easy to enter cells and exert their effects. 20 The (SOAT) complex can form smaller nanoparticles (100nm-300nm) at different mass ratios (w / w=5:1, 8:1, 10:1, 12:1 and 15:1) and is positively charged, which is conducive to cellular endocytosis.

[0080] Test Example 2 In vitro antibacterial activity test

[0081] Two common anaerobic pathogens of periodontitis were selected: Porphyromonas gingivalis (P.gingivalis) and Actinobacillus actinomycetemcomitans (Aa). 20 -1(SOAT) was mixed with the bacterial solution and cultured in a bacterial culture incubator at 37°C for 4 h. The bacterial solution of each group was plated and the culture dish was cultured at 37°C until obvious single colonies grew. The culture dish was photographed and counted. Figure 3 Graph showing the antibacterial properties of polycation / cascade protein formulations against Aa and P. gingivalis.

[0082] from Figure 3 It can be seen that:

[0083] For Actinobacillus actinomycetemcomitans (Aa), β-CD-g-PSS at a concentration of 256 μg / mL 20 -1(SOAT) can kill all Aa bacteria. 20 -1(SOAT) has a good Aa bactericidal effect at a concentration of 256 μg / mL or more.

[0084] For Porphyromonas gingivalis (P. gingivalis), at a concentration of 2048 μg / mL, β-CD-g-PSS 20 -1(SOAT) kills all P.gingivalis bacteria. Description β-CD-g-PSS 20 -1(SOAT) has a good Aa bactericidal effect at a concentration of 2048 μg / mL or more.

[0085] In summary, β-CD-g-PSS20 -1(SOAT) has excellent antibacterial properties and can effectively eliminate periodontitis pathogens.

[0086] Test Example 3 In vitro anti-inflammatory activity test

[0087] The TNF-α level in mouse mononuclear macrophage leukemia cells (RAW 264.7) after different treatments was measured using an enzyme-linked immunosorbent assay kit (ELISA) for inflammatory factors.

[0088] RAW 264.7 cells were inoculated into 24-well plates. After 12 hours of culture, the culture medium was removed from the remaining wells except the Blank group, and LPS diluted in DMEM culture medium (final concentration was 200 ng / mL) was added. The cells were cultured in a 37°C cell culture incubator for 12 hours to construct an LPS-induced oxidative damage cell model. Then, the culture medium containing LPS was replaced with SOAT, β-CD-g-PSS, and β-CD-g-PSS according to the group. 20 -1(SOD),β-CD-g-PSS 20 -1(CAT) and β-CD-g-PSS 20 -1 (SOAT) fresh culture medium, after culturing for 4 hours, the cell supernatant was taken and the test was performed according to the operating steps of the kit to evaluate the level of TNF-α secreted by the cells after different treatments. Figure 4 Graph showing the anti-inflammatory properties of polycation / cascade protein formulations.

[0089] from Figure 4 It can be seen that:

[0090] In SOAT, β-CD-g-PSS 20 -1(SOD) and β-CD-g-PSS 20 After treatment with -1(CAT), the TNF-α of cells decreased slightly to about 9354pg / mL, 9586pg / mL and 8157pg / mL, which came from the elimination of ROS by SOD and CAT, respectively, but the downregulation was limited. 20 -1 (SOAT) decreased the most significantly, to about half of the level before treatment (about 5696pg / mL). This shows that the SOAT protein of the present invention has both SOD and CAT enzyme activities, and compared with SOD and CAT alone, it removes more ROS through cascade catalysis, better alleviates the oxidative damage of ROS to cells, and reduces the level of cell inflammation.

[0091] Test Example 4 In vitro safety test

[0092] Determination of β-CD-g-PSS by MTT method20 -1(SOAT) cytotoxicity was studied by incubating rat gingival fibroblasts (RGF) and mouse mononuclear macrophage leukemia cells (RAW 264.7) at 1×10 4 The cells were inoculated at a density of 100 μL / well in a 96-well plate, and 100 μL DMEM cell culture medium (containing 10% FBS and 1% double antibody) was added to each well. After culturing in a 37°C cell culture incubator for 24 h, the culture medium was replaced with a pre-prepared β-CD-g-PSS. 20 -1 (SOAT) fresh culture medium, continue to culture for 4 hours, carefully remove the old culture medium and replace it with fresh DMEM. After continuing to culture for 20 hours, aspirate the culture medium, add MTT solution, and culture at 37°C for 4 hours. Replace the MTT solution with DMSO, shake to dissolve the coloring substance, and read the OD using an enzyme reader 570 And the relative cell viability was calculated. Figure 5 Figure 2 shows the cytotoxicity of polycation / cascade protein preparations. Figure 5 It can be seen that:

[0093] In the RGF cell line and immune cell line RAW 264.7, β-CD-g-PSS 20 -1 (SOAT) cell survival rates were all over 80% (RGF cell line survival rate was about 82%, RAW 264.7 cell line survival rate was about 86%. This shows that the β-CD-g-PSS of the present invention 20 -1(SOAT) has less toxicity at antibacterial concentrations and can be used safely.

[0094] Test Example 5 Particle Size Potential Characterization

[0095] The polycation / cascade protein complex prepared in Example 6-9 was diluted and 1 mL was taken out to measure the hydrated particle size and surface potential on a Malvern dynamic light scattering instrument. The polycation / cascade protein complex prepared in Example was diluted and 1 mL was taken out to measure the hydrated particle size and surface potential on a Malvern dynamic light scattering instrument. Figure 6 Particle size potential plots for polycation / cascade protein preparations.

[0096] from Figure 6 It can be seen that:

[0097] Mixing PHMB with SOAT can produce positively charged nanoparticles, which are easy to enter cells and exert their effects. The PHMB (SOAT) complex can be formed into smaller nanoparticles (100nm to 300nm) at different mass ratios (w / w = 5:1, 7.5:1, 10:1 and 15:1), and is positively charged, which is conducive to cell endocytosis.

[0098] Test Example 6 In vitro antibacterial activity test

[0099] The minimum bactericidal concentration (MBC) was used to evaluate the antibacterial properties of PHMB-1 (SOAT). A single MRSA colony was selected and added to liquid LB medium and cultured in a constant temperature shaker for 12 h. MRSA was resuspended in PBS to 2×10 8 CFU / mL concentration, then add PHMB-1(SOAT) with different PHMB concentrations to a 96-well plate, add 60 μL of bacterial suspension, and culture for 12 hours. Take 5 μL to spot on solid LB medium, incubate for 12 hours and take pictures. Figure 7 Antimicrobial profile of the polycation / cascade protein formulation.

[0100] from Figure 7 It can be seen that:

[0101] At a concentration of 16 μg / mL of PHMB, PHMB-1 (SOAT) effectively kills MRSA bacteria, indicating that PHMB-1 (SOAT) of the present invention has a good ability to kill MRSA bacteria at a concentration of 16 μg / mL or more, and can effectively eliminate MRSA pathogens.

[0102] Test Example 7 In vitro safety test

[0103] The cytotoxicity of PHMB-1 (SOAT) was determined using the CCK8 method. Rat BMSC cells were cultured at a concentration of 1×10 4 Cells were inoculated at a density of 100 μL / well in a 96-well plate, and 100 μL DMEM cell culture medium (containing 10% FBS and 1% double antibody) was added to each well. After culturing in a 37°C cell culture incubator for 24 hours, the culture medium was replaced with fresh culture medium containing pre-configured PHMB-1 (SOAT). After culturing for another 4 hours, the old culture medium was carefully removed and replaced with fresh DMEM. After culturing for another 20 hours, the culture medium was aspirated, and 100 μL of the prepared culture medium with CCK8 was added to each well. The volume ratio of the culture medium to CCK was 10:1. The OD was read using an enzyme reader. 450 , calculate the relative cell viability. Figure 8 Figure 2 shows the cytotoxicity of polycation / Cascade protein formulations.

[0104] from Figure 8 It can be seen that:

[0105] In rat BMSC cells, the cell survival rate of PHMB-1 (SOAT) exceeded 70%, indicating that the PHMB-1 (SOAT) of the present invention has less toxicity at the antibacterial concentration and can be used safely.

[0106] In summary, based on the results of in vitro antibacterial and anti-inflammatory properties, the polycationic / cascade protein preparation β-CD-g-PSS with antibacterial and anti-inflammatory functions of the present invention is20 (SOAT) and PHMB(SOAT) are safe to use.

[0107] Finally, it should be noted that the above preferred embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described in detail through the above preferred embodiments, those skilled in the art should understand that various changes can be made in form and details without departing from the scope defined by the claims of the present invention.

Claims

1. A method for preparing a polycationic / cascade protein preparation having antibacterial and anti-inflammatory functions, It is characterized in that The positively charged polycation and cascade protein form a complex through electrostatic interaction. The preparation steps are as follows: 1) preparing a cascade protein, wherein the cascade protein is a cascade protein expressed by a superoxide dismutase and catalase fusion plasmid; 2) The polycation and the cascade protein are separately prepared into solutions, and mixed at a mass ratio of 5:1 to 15:1 to obtain polycation / cascade protein.

2. A method for preparing a polycationic / cascade protein preparation having antibacterial and anti-inflammatory functions according to claim 1, It is characterized in that The molecular weight of the cascade protein in step 1) is 80 kDa.

3. A method for preparing a polycationic protein preparation having antibacterial and anti-inflammatory functions according to claim 1, It is characterized in that The polycation and cascade protein described in step 2) are mixed at a mass ratio of 5:

1.

4. A method for preparing a polycationic / cascade protein preparation having antibacterial and anti-inflammatory functions according to claim 1, It is characterized in that The concentration of the cascade protein solution in step 2) is 1-5 mg / mL, and the concentration of the polycation solution is 1-5 mg / mL.

5. A method for preparing a polycationic / cascade protein preparation having antibacterial and anti-inflammatory functions according to claim 1, It is characterized in that The polycation described in step 2) is β-CD-g-PSS 20 or polyhexamethylene biguanide, the β-CD-g-PSS 20 The structural formula is: The number average molecular weight of the polyhexamethylene biguanide is 2190-2928.

6. A method for preparing a polycationic / cascade protein preparation having antibacterial and anti-inflammatory functions according to claim 1, It is characterized in that The β-CD-g-PSS 20 The preparation method comprises the following steps: using all-thiol-β-cyclodextrin as an initiator, initiating monomer lipoic acid-arginine to carry out disulfide exchange polymerization at 25-35°C, and using 2-iodoacetamide to terminate the polymerization.

7. A method for preparing a polycationic / cascade protein preparation having antibacterial and anti-inflammatory functions according to claim 1, It is characterized in that The preparation method of the cascade protein described in step 1) is to construct the sequences of superoxide dismutase and catalase into a prokaryotic expression vector, then express the cascade protein with competent cells, and obtain the cascade protein by nickel column purification.

8. A polycationic / cascade protein preparation with antibacterial and anti-inflammatory functions prepared according to any one of claims 1 to 7, It is characterized in that The particle size is 100-500nm.

9. Use of the polycationic / cascade protein preparation with antibacterial and anti-inflammatory functions according to claim 8 in preventing periodontitis and osteomyelitis.

10. Use of a polycationic / cascade protein preparation with antibacterial and anti-inflammatory functions according to claim 8 in preventing periodontitis and osteomyelitis, It is characterized in that The polycation is β-CD-g-PSS 20 When the polycation in the preparation is polyhexamethylene biguanide, it is used to prevent osteomyelitis.